Eupraxia Pharmaceuticals (NASDAQ:EPRX) Earns Speculative Buy Rating from Analysts at Canaccord Genuity Group
Canaccord Genuity Group started coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) in a research note released on Monday morning, Marketbeat Ratings reports. The firm issued a speculative buy rating on the stock. Separately, Craig Hallum began coverage on shares of Eupraxia Pharmaceuticals in a research report on Friday, February 21st. They set […]
Canaccord Genuity Group started coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) in a research note released on Monday morning, Marketbeat Ratings reports. The firm issued a speculative buy rating on the stock. Separately, Craig Hallum began coverage on shares of Eupraxia Pharmaceuticals in a research report on Friday, February 21st. They set […]
